Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
|
|
- Robyn Hall
- 5 years ago
- Views:
Transcription
1
2 Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
3 Learning Objectives Describe best practices for diagnosing IPF based on the most recent evidence-based guidelines Develop a comprehensive assessment and diagnosis strategy to differentiate IPF from other interstitial lung diseases Develop a comprehensive approach to management of IPF based on the most recent clinical data to include pharmacologic and non-pharmacologic therapies Determine appropriate strategies for the multidisciplinary healthcare team to effectively educate patients with IPF about their disease and address quality of life issues
4 Learning Objectives Review Guidelines for the Treatment of IPF Overview of IPF Pathophysiology Review the two FDA-approved anti-fibrotic therapies for IPF Proposed mechanism of action Outcomes from the clinical trials Management Expectations Side Effects Review recommended non-pharmacologic therapies Lung Transplant Oxygen therapy Pulmonary Rehabilitation Co-morbidities (?)
5 Guidelines for the Treatment of IPF Raghu G, et al. Am J Respir Crit Care Med. 2015;192:
6 Strong vs. Conditional Recommendations Raghu G, et al. Am J Respir Crit Care Med. 2015;192:
7 Conventional Pharmacological Therapies Treatment Lung Transplantation Long-term oxygen for hypoxemia Pulmonary Rehabilitation Comorbidity Therapy GERD Pirfenidone Nintedanib (TKI multiple targets) Sildenafil (PDE-5 inhibitor) Macitentan/Bosentan (Dual ERA) NAC alone NAC/Azathioprine/Prednisone Corticosteroids Warfarin (Anticoagulation) Ambrisentan (Selective ERA) Imatinib (TKI one target) Strong For Conditional For Weak Against Strong Against Raghu G, et al. Am J Respir Crit Care Med. 2011;183: Raghu G, et al. Am J Respir Crit Care Med. 2015;192:
8 Pathophysiology of IPF This image has been adapted and reprinted with permission of the American Thoracic Society. Copyright 2017 American Thoracic Society. Ahluwalia N, et al./2014/new Therapeutic Targets in Idiopathic Pulmonary Fibrosis/Am J Respir Crit Care Med/190/ The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
9 IPF Histopathology Courtesy of Steve Groshong, MD, NJH.
10 Anti-Fibrotic Therapies Treatment Lung Transplantation Long-term oxygen for hypoxemia Pulmonary Rehabilitation Comorbidity Therapy GERD Pirfenidone Nintedanib (TKI multiple targets) Sildenafil (PDE-5 inhibitor) Macitentan/Bosentan (Dual ERA) NAC alone NAC/Azathioprine/Prednisone Corticosteroids Warfarin (Anticoagulation) Ambrisentan (Selective ERA) Imatinib (TKI one target) Strong For Conditional For Weak Against Strong Against Raghu G, et al. Am J Respir Crit Care Med. 2011;183: Raghu G, et al. Am J Respir Crit Care Med. 2015;192:
11 Pharmacologic Therapies - Pirfenidone Anti-fibrotic Anti-inflammatory Anti-oxidant
12 Pathophysiology of IPF This image has been adapted and reprinted with permission of the American Thoracic Society. Copyright 2017 American Thoracic Society. Ahluwalia N, et al./2014/new Therapeutic Targets in Idiopathic Pulmonary Fibrosis/Am J Respir Crit Care Med/190/ The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
13 Capacity I & II: Pirfenidone Based on this data, the FDA did not approve Pirfenidone and a 3 rd study was required (Ascend) Mean change from baseline in percentage predicted FVC in study 004 (A), study 006 (B), and the pooled population (C) FVC=forced vital capacity. *Pirfenidone 2403 mg/day versus placebo. Rank ANCOVA (pirfenidone 2403 mg/day vs placebo). 95% CIs were only calculated for absolute differences for the week 72 timepoint in study 004 (0 7 to 9 1) and study 006 ( 3 5 to 4 7). Reprinted from The Lancet, 377, Nobel PW, et al., Pirfenidone in patients with Idiopathic Pulmonary Fibrosis (CAPACITY): two randomised trials, , Copyright 2011, with permission from Elsevier.
14 Ascend: Pirfenidone Primary Endpoint Was Achieved Patients with 10% FVC Decline or Death (%) Mean Change in FVC from Baseline 235 ml vs. 428 ml* 48% Relative Reduction. * For deaths, FVC = 0. From The New England Journal of Medicine, King TE, et al., A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, 370, Copyright 2014 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society
15 Side Effects Adverse Event Pirfenidone (N=278) Placebo (N=277) Nausea 36% 13.4% Rash 28.1% 8.7% Dyspepsia % 6.1% GERD 11.9% 6.5% In addition to nausea and dyspepsia, subjects on therapy also had an increased incidence of anorexia, vomiting, and decrease in weight The rash is typically a photosensitivity rash that results in a macular-type exanthema with flaking plaques, and can be extremely pruritic Discontinuation due to side effects was 14.4% King TE, et al. N Engl J Med. 2014;370: Koulelidis A, et al.
16 Pharmacologic Therapies - Nintedanib Triple Tyrosine Kinase Inhibitor Vascular Endothelial Growth Factor (VEGF) Platelet Derived Growth Factor (PDGF) Fibroblast Growth Factor (FGF)
17 Pathophysiology of IPF This image has been adapted and reprinted with permission of the American Thoracic Society. Copyright 2017 American Thoracic Society. Ahluwalia N, et al./2014/new Therapeutic Targets in Idiopathic Pulmonary Fibrosis/Am J Respir Crit Care Med/190/ The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
18 INPULSIS 1 & 2: Nintedanib Primary Endpoint Was Achieved 52% Relative Reduction 45% Relative Reduction From The New England Journal of Medicine, Richeldi, et al., Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis, 370, Copyright 2014 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society
19 Side Effects: Gastrointestinal Discontinuation due to side effects was 21%. Adverse Event * Nintedanib (N=309) Placebo (N=204) Any 96% 89% Diarrhea 62% 19% Nausea 23% 6% * Adverse event data from INPULSIS 1; similar to INPULSIS 2. Richeldi L, et al. N Engl J Med ;370:
20 Side Effects: Bleeding Theoretical risk with nintedanib given inhibition of PDGF and VEGF Patients on anticoagulation were excluded from INPULSIS studies Bleeding Events Epistaxis Contusion Serious Bleeding Nintedanib 10.3% 4.1% 1.6% 1.3% Placebo 7.8% 3.1% 0.9% 1.4% Corte T, et al. Respiratory Research. 2015; 16:116.
21 Side Effects: Additional Myocardial Infarction Fatal adverse cardiac events INPULSIS I INPULSIS II Nintedanib 0.3% (n=1) 0.6% (n=2) Placebo 1% (n=2) 1.8% (n=4) Other cardiovascular events were similar between the treatment and placebo groups. Richeldi L, et al. N Engl J Med ;370:
22 Side Effects - Liver Toxicity Pirfenidone Pirfenidone vs. Placebo AST/ALT > 3 x upper limits of normal (2.9% vs. 0.7%) All elevations were reversible Lead to discontinuation in 1% of patients Monitoring LFTs q month x 6 months LFTs q 3 months Nintedanib Nintedanib vs. Placebo AST/ALT > 3 x upper limits of normal INPULSIS 1 (4.9% vs. 0.5%) INPULSIS 2 (5.2% vs. 0.9%) Monitoring LFTs q month x 3 months LFTs q 3 months
23 Management of Side Effects Patient Education Adjunctive Medications/Food Diarrhea with Nintedanib Loperamide Nausea with Pirfenidone Ensure medications taken within the meal If a side effect occurs, adjust dose If it persists, temporary interrupt therapy Once resolved, slow re-escalation Permanent discontinuation for recurrent or severe side effects
24 Management of Expectations These anti-fibrotics MAY Slow down progression of disease Cause significant side-effects These anti-fibrotics WON T Make a patient feel better May or may not make a patient live longer Thus, the conditional recommendation
25 Mr. Slide H Has Title Been Newly Diagnosed With IPF. What Is His Likely Response? 1. Mr. H may not want to take pirfenidone due to the phototoxocity. 2. Mr. H may not want to take pirfenidone due to the number of pills/frequency of dosing. 3. Mr. H may not want to take nintedanib due to his cardiac history. 4. Mr. H may not want to take nintedanib due to concerns for diarrhea. 5. All of the above.
26 Mr. Slide H Has Title Been Newly Diagnosed With IPF. What Is His Likely Response? 1. Mr. H may not want to take pirfenidone due to the phototoxocity. 2. Mr. H may not want to take pirfenidone due to the number of pills/frequency of dosing. 3. Mr. H may not want to take nintedanib due to his cardiac history. 4. Mr. H may not want to take nintedanib due to concerns for diarrhea. 5. All of the above.
27 Conventional Non-Pharmacological Therapies Treatment Lung Transplantation Long-term oxygen for hypoxemia Pulmonary Rehabilitation Comorbidity Therapy GERD Pirfenidone Nintedanib (TKI multiple targets) Sildenafil (PDE-5 inhibitor) Macitentan/Bosentan (Dual ERA) NAC alone NAC/Azathioprine/Prednisone Corticosteroids Warfarin (Anticoagulation) Ambrisentan (Selective ERA) Imatinib (TKI one target) Strong For Conditional For Weak Against Strong Against Raghu G, et al. Am J Respir Crit Care Med. 2011;183: Raghu G, et al. Am J Respir Crit Care Med. 2015;192:
28 Lung Transplantation The only therapy that prolongs survival in IPF IPF is now the number one diagnosis for transplant Five-year survival is ~ 50% Many centers are transplanting older patients (>65) Chambers DC, et al. J Heart Lung Transplant Oct;36(10): King TE Jr, et al. Lancet. 2011;378:
29 Lung Transplantation: When To Refer At the time of diagnosis Evaluation (due to unpredictable course) As disease progresses Listing (based on Lung Allocation Score) Chambers DC, et al. J Heart Lung Transplant Oct;36(10): Reprinted from The Lancet, 378, King TE Jr, et al., Idiopathic Pulmonary Fibrosis, , Copyright 2011, with permission from Elsevier.
30 Oxygen Therapy Ensure oxygen saturations are > 90% at all times Rest, Ambulation, Exercise, Sleep Obstructive Sleep Apnea (OSA) is common in IPF Patients may not present with typical symptoms Untreated OSA may be associated with worse prognosis Mortality & Clinical Progression While this is a Strong Recommendation, limited data No proven survival benefit Evidence does exist that it may improve exercise capacity/reduces dyspnea At present, Ongoing studies Calls for more research Raghu G, et al. Am J Respir Crit Care Med. 2011;183: Bosi M, et al. Lung Jul 3. [Epub ahead of print]. Dowman LM, et al. Respirology. 2017;22:
31 Pulmonary Rehabilitation Most programs meet 2-3 times per week for 4 to 12 weeks or more... Improves quality of life Increases walk distance Decreases breathlessness Decreases depression Duration of benefit? Image from: ATS Patient Information Series. Dowman L, et al. Cochrane Database Sys Rev Oct 6;(10). Olson AL, et al. Patient Relat Outcome Meas May 17; Raghu G, et al. Am J Respir Crit Care Med. 2011;183:
32 Comorbidities: Gastroesophageal Reflux Disease (GERD) Higher prevalence in IPF Distal GER reported as high as 88% of patients Proximal GER reported as high as 71% of patients May be silent Hypothesized to play a role in progressive lung fibrosis IPF treatment recommendations Conditional for the treatment of reflux Lee JS, et al. Am J Respir Crit Care. 2011;184:
33 Pathophysiology of IPF This image has been adapted and reprinted with permission of the American Thoracic Society. Copyright 2017 American Thoracic Society. Ahluwalia N, et al./2014/new Therapeutic Targets in Idiopathic Pulmonary Fibrosis/Am J Respir Crit Care Med/190/ The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.
34 Other Comorbidities Comorbidities Relative Risk (95% CI) Pulmonary Hypertension ( )* Pulmonary Embolism 6.97 ( )* Pulmonary Infections 4.20 ( )* Heart Failure 3.83 ( )* Sleep Apnea 3.65 ( )* Lung Cancer 2.83 ( )* Myocardial Infarction 2.13 ( )* Coronary Artery Disease 1.86 ( )* Depression 1.40 ( )* Collard H, et al. J Med Econ. 2012;15:
35 IPF Future We have no known pharmacologic therapy to halt disease Still much work to be done Consider discussing with patients a referral for a clinical trial
36 Summary For patients with IPF Two FDA approved anti-fibrotic therapies are available Equipoise on the efficacy Shared decision making between the physician and patient regarding treatment/agent Keeping patients on therapy requires Expectation management Side effect management Remember the non-pharmacologic therapies & to identify and treat comorbidities Always consider ongoing clinical trials in IPF
37 For additional resources and IPF patient education materials, please visit
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More informationManagement of Idiopathic Pulmonary Fibrosis
Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1
More informationDisclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF
IPF Medications: Practical Experience Disclosures Received speakers bureau honorarium from Roche/Genentech (makers of pirfenidone). Brett Ley, MD, MAS Assistant Professor, UCSF 67 y/o man 1 year cough
More informationPerspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
More informationOfficial ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis
Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline Online Supplement Ganesh Raghu, Bram Rochwerg, Yuan
More informationEvaluating New Treatment Options
Evaluating New Treatment Options Steven D. Nathan, MD Clinical Practice Guideline Changes 211 ATS/ERS/JRS/ALAT Recommendations Treatment of IPF combines nonpharmacologic and pharmacologic strategies, and
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationWim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.
nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationA PARTNERSHIP PLAN FOR IDIOPATHIC PULMONARY FIBROSIS
A PARTNERSHIP PLAN FOR IDIOPATHIC PULMONARY FIBROSIS A STRATEGY FOR DEVELOPING AN IPF MANAGEMENT PLAN BASED ON REALISTIC PATIENT GOALS Indication Esbriet (pirfenidone) is indicated for the treatment of
More informationExperience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina
ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib
More informationRole of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study
36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E
More informationTracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust
Interstitial Lung Disease (ILD) Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust The views expressed in this presentation are those of the speaker and are not necessarily those
More informationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationNew Drug Evaluation: Pirfenidone capsules, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIdiopathic pulmonary fibrosis
Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis This chronic disease has historically lacked an effective treatment option, but the FDA recently approved two: pirfenidone and nintedanib. This
More informationRegulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)
More informationInvestor Update. Services. Investor Relations team Send . Basel, 24 May Subscribe to Roche news
Investor Update Basel, 24 May 2017 New data at ATS add to the body of evidence for Roche s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet
More informationEmerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow
Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the tissue that supports the lungs alveoli
More informationManuscript Draft. Title: What if we made stratified medicine work for patients?
Respiratory Medicine Elsevier Editorial System(tm) for The Lancet Manuscript Draft Manuscript Number: Title: What if we made stratified medicine work for patients? Article Type: Comment Keywords: stratified
More informationCADTH CDEC FINAL RECOMMENDATION
CADTH CDEC FINAL RECOMMENDATION NINTEDANIB (Ofev Boehringer Ingelheim Canada Ltd.) Indication: Idiopathic Pulmonary Fibrosis Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends that
More informationPresente e futuro della terapia della fibrosi polmonare idiopatica
Presente e futuro della terapia della fibrosi polmonare idiopatica Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp.
More informationKD : A Phase 2 Trial of KD025 to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF)
-207: A Phase 2 Trial of to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF) K. F. Gibson 1, F. Averill 2, T.E. Albertson 3, D. M. Baratz 4, S. Chaudhary 5,
More informationOFEV Frequently Asked Questions (FAQs)
OFEV Frequently Asked Questions (FAQs) INDICATION AND USAGE OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). WARNINGS AND PRECAUTIONS Hepatic Impairment OFEV is not recommended
More informationMalattie respiratorie: terapia e aderenza terapeutica nel paziente anziano
La Cronicità: Dall Ospedale al territorio, una realtà in evoluzione Malattie respiratorie: terapia e aderenza terapeutica nel paziente anziano Dr. Sergio Harari U.O. di Pneumologia Ospedale San Giuseppe
More informationTODAY IS THE DAY I STAND UP TO IPF. fightipf.ca. Talking to your doctor about IPF and your options
fightipf.ca SUPPORTING PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS TODAY IS THE DAY I STAND UP TO IPF Talking to your doctor about IPF and your options WHAT IT MEANS TO HAVE IPF Idiopathic Pulmonary Fibrosis,
More informationSummary: Key Learning Points, Clinical Strategies, and Future Directions
Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung
More informationStrategies for Updated Treatment Options for IPF
Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Idiopathic Pulmonary Fibrosis Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective
More informationIdiopathic pulmonary fibrosis (IPF) is a progressive. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Eur Respir Rev 2012; 21: 124, 161 167 DOI: 10.1183/09059180.00001112 CopyrightßERS 2012 REVIEW: IPF Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Vincent
More informationPirfenidone: an update on clinical trial data and insights from everyday practice
REVIEW IDIOPATHIC PULMONARY FIBROSIS Pirfenidone: an update on clinical trial data and insights from everyday practice Michael Kreuter 1,2 Affiliations: 1 Dept of Pneumology and Respiratory Critical Care
More informationChallenges in Pulmonary and Critical Care: 2018
Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationWhen to start and when to stop antifibrotic therapies
REVIEW ANTIFIBROTIC THERAPIES When to start and when to stop antifibrotic therapies Sebastiano Emanuele Torrisi, Mauro Pavone, Ada Vancheri and Carlo Vancheri Affiliation: Regional Referral Centre for
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationContemporary Clinical Trials Communications
Contemporary Clinical Trials Communications 3 (2016) 80e85 Contents lists available at ScienceDirect Contemporary Clinical Trials Communications journal homepage: www.elsevier.com/locate/conctc Idiopathic
More informationDo randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis
Page 1 of 6 AJRCCM Articles in Press. Published on 25-August-2017 as 10.1164/rccm.201708-1666ED Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationTitle: Diagnosis, management and attitudes about idiopathic pulmonary fibrosis among Turkish pulmonologists
1 Manuscript type: Original Article DOI: 10.5152/TurkThoracJ.2019.180181 Title: Diagnosis, management and attitudes about idiopathic pulmonary fibrosis among Turkish pulmonologists Short title: Idiopathic
More information9/12/18. Emerging Challenges in Primary Care: Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis
Emerging Challenges in Primary Care: 2018 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical
More informationcontinuing education for pharmacists
continuing education for pharmacists New Drugs to Treat Idiopathic Pulmonary Fibrosis: Esbriet and Ofev Thomas A. Gossel, R.Ph., Ph.D., Professor Emeritus, Ohio Northern University, Ada, Ohio Volume XXXIII,
More informationCurrent Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine
Current Management of IPF and fibrosing ILDs Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Introduction Idiopathic pulmonary fibrosis clinical course is variable and long term survival is poor Therapy
More informationGLPG1690 FLORA topline results
GLPG1690 FLORA topline results Webcast presentation 10 August 2017 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the potential activity
More informationEvidence-based treatment strategies in idiopathic pulmonary fibrosis
Eur Respir Rev 2013; 22: 128, 163 168 DOI: 10.1183/09059180.00001013 CopyrightßERS 2013 REVIEW Evidence-based treatment strategies in idiopathic pulmonary fibrosis Jürgen Behr ABSTRACT: Recently updated
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationPharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
REVIEW IDIOPATHIC PULMONARY FIBROSIS Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Ganesh Raghu Affiliation: Center for Interstitial Lung Diseases, University
More informationIDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
More informationRandomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
original article Randomized Trial of in Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* ABSTRACT Background has been suggested as a beneficial treatment for idiopathic
More informationOn behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. August 2017
On behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand Treatment of Idiopathic Pulmonary Fibrosis in Australia and New Zealand from the Thoracic Society of Australia
More informationUntil approximately 40 yrs ago, clinical. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis REVIEW: IPF
Eur Respir Rev 2012; 21: 124, 147 151 DOI: 10.1183/09059180.00000912 CopyrightßERS 2012 REVIEW: IPF Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis Luca Richeldi ABSTRACT:
More informationCommon Drug Review Clinical Review Report
Common Drug Review Clinical Review Report October 2015 Drug nintedanib (Ofev) Indication For the treatment of idiopathic pulmonary fibrosis (IPF). Listing request For adult patients who have a diagnosis
More informationNAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis
NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis Mark J Rumbak, MD Division Director Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine University of South Florida, Tampa
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationRelative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
Thorax Online First, published on March 22, 2012 as 10.1136/thoraxjnl-2011-201184 Interstitial lung disease < Additional materials are published online only. To view these files please visit the journal
More informationPNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera
PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e
More informationA BS TR AC T. n engl j med 365;12 nejm.org september 22,
The new england journal of medicine established in 1812 september 22, 2011 vol. 365 no. 12 Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis Luca Richeldi, M.D., Ph.D., Ulrich Costabel,
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationPrise en charge globale du patient dans la Fibrose interstitielle diffuse Comprehensive care for patients with pulmonary fibrosis
Prise en charge globale du patient dans la Fibrose interstitielle diffuse Comprehensive care for patients with pulmonary fibrosis Marlies Wijsenbeek Centre of Interstitial Lung Diseases Erasmus MC, Rotterdam,
More informationKD025 in IPF: Topline Results
KD025 in IPF: Topline Results Webcast Presentation February 13, 2018 Kadmon Holdings, Inc. 1 Forward-looking Statement This presentation contains forward looking statements that are based on the beliefs
More informationTODAY IS THE DAY I STAND UP TO IPF. fightipf.co.uk
fightipf.co.uk SUPPORTING IPF AWARENESS TODAY IS THE DAY I STAND UP TO IPF For people diagnosed with Idiopathic Pulmonary Fibrosis: A guide to help you discuss your condition and management options with
More informationPIRFENIDONE. London New Drugs Group APC/DTC Briefing Document. December 2011
Page 1 London New Drugs Group APC/DTC Briefing Document PIRFENIDONE Contents Summary 1 Background 4 Current Therapy 4 Pirfenidone 4 CAPACITY studies 5 Supportive studies 7 Safety 9 Place in therapy 9 Reference
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationIdiopathic pulmonary fibrosis: recent advances on pharmacological therapy
Accepted Manuscript Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy P. Spagnolo, T.M. Maher, L. Richeldi PII: S0163-7258(15)00091-1 DOI: doi: 10.1016/j.pharmthera.2015.04.005
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationRespiratory Subcommittee of PTAC Meeting held 4 March 2015
Respiratory Subcommittee of PTAC Meeting held 4 March 2015 (minutes for web publishing) Respiratory Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and
More informationFaculty. Luca Richeldi, MD, PhD (Chair) Professor of Respiratory Medicine Chair of Interstitial Lung Disease University of Southampton Southampton, UK
Faculty Luca Richeldi, MD, PhD (Chair) Professor of Respiratory Medicine Chair of Interstitial Lung Disease University of Southampton Southampton, UK Kevin K. Brown, MD Professor of Medicine, Vice Chair,
More informationIdiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age
Review Article Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age Jonathon Shaw, Tracey Marshall, Helen Morris, Conal Hayton, Nazia Chaudhuri North West Interstitial
More informationMissing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough
EDITORIAL INTERSTITIAL LUNG DISEASE Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough Gabriel Thabut 1,2, Bruno Crestani 2,3, Raphaël Porcher 4,5 and
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationThe Importance of Pulmonary Rehabilitation
November 21, 2017 The Importance of Pulmonary Rehabilitation Presenter: George Pyrgos, MD 1 The importance of Pulmonary Rehabilitation George Pyrgos, MD Medical Director of the Angelos Lung Center at Medstar
More informationPirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASE Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Paul W. Noble 1, Carlo Albera 2, Williamson Z.
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationSupported by an educational grant from
IDIOPATHIC PULMONARY FIBROSIS: PATIENT INFORMATION BROCHURE Supported by an educational grant from 08232-106 CONTENTS What is Pulmonary Fibrosis?.......................................................
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationIdiopathic pulmonary fibrosis (IPF) is a complex, progressive
Strategies to Manage Costs in Idiopathic Pulmonary Fibrosis Gary M. Owens, MD Idiopathic pulmonary fibrosis (IPF) is a complex, progressive disease, challenging to diagnose, due to the need to exclude
More informationPulmonary hypertension in sarcoidosis
Pulmonary hypertension in sarcoidosis Olivier SITBON Centre de Référence de l Hypertension Pulmonaire Sévère Hôpital Universitaire de Bicêtre INSERM U999 Université Paris-Sud Le Kremlin-Bicêtre France
More informationDiscipline MCP5777 In-depth Study of the Treatment of Interstitial Idiopathic Pulmonary Fibrosis. Duration Total
Discipline MCP5777 In-depth Study of the Treatment of Interstitial Idiopathic Pulmonary Fibrosis Subject Area: 5150 Created: 27/11/2014 Active since: 27/11/2014 Number of credits: 1 Hours: Theoretical
More informationRecognition of drug-induced pulmonary disease and management of idiopathic pulmonary fibrosis
CREDIT: 2.0 Continuing Education EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS educational objectives
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationCome gestire le comorbidità e il follow-up
Come gestire le comorbidità e il follow-up Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp. San Giuseppe - MultiMedica,
More informationScleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology
Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma 1 Scleroderma Chronic systemic autoimmune disease
More informationScleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma.
Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma Chronic systemic autoimmune disease characterized
More informationChallenges in Pulmonary and Critical Care 2017
Challenges in Pulmonary and Critical Care 2017 Idiopathic Pulmonary Fibrosis: New Advances in Therapy Outcome Report: Boehringer Ingelheim Grant # ME201722329 February 2, 2018 Level 1 (Participation) Practice
More informationACUTE RESPIRATORY DISTRESS SYNDROME
ACUTE RESPIRATORY DISTRESS SYNDROME Angel Coz MD, FCCP, DCE Assistant Professor of Medicine UCSF Fresno November 4, 2017 No disclosures OBJECTIVES Identify current trends and risk factors of ARDS Describe
More informationCosa accade nella real life?
Cosa accade nella real life? Sergio Harari U.O. di Pneumologia UTIR Servizio di Fisiopatologia Respiratoria e Emodinamica Polmonare Ospedale San Giuseppe MultiMedica Milano Sorrento Breathings 7-9 Aprile
More informationTake on IPF progression with OFEV
Every breath matters Take on IPF progression with OFEV Learn more at www.ofev.com IPF=idiopathic pulmonary fibrosis. Please see throughout Understand how IPF affects you Idiopathic pulmonary fibrosis (IPF)
More informationSleep Apnea: Vascular and Metabolic Complications
Sleep Apnea: Vascular and Metabolic Complications Vahid Mohsenin, M.D. Professor of Medicine Yale University School of Medicine Director, Yale Center for Sleep Medicine Definitions Apnea: Cessation of
More informationCONNECTIONS. New Hope for Prevention of Childhood Food Allergies
National Jewish Health A newsletter for physicians CONNECTIONS Summer 2015 New Hope for Prevention of Childhood Food Allergies Emerging evidence suggests that early introduction of potentially allergenic
More information